TY - JOUR
T1 - Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA
AU - Jann, Johann Christoph
AU - Nowak, Daniel
AU - Nolte, Florian
AU - Fey, Stephanie
AU - Nowak, Verena
AU - Obländer, Julia
AU - Pressler, Jovita
AU - Palme, Iris
AU - Xanthopoulos, Christina
AU - Fabarius, Alice
AU - Platzbecker, Uwe
AU - Giagounidis, Aristoteles
AU - Götze, Katharina
AU - Letsch, Anne
AU - Haase, Detlef
AU - Schlenk, Richard
AU - Bug, Gesine
AU - Lübbert, Michael
AU - Ganser, Arnold
AU - Germing, Ulrich
AU - Haferlach, Claudia
AU - Hofmann, Wolf Karsten
AU - Mossner, Maximilian
N1 - Publisher Copyright:
© Article author(s).
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background C ytogenetic aberrations such as deletion of chromosome 5q (del(5q)) represent key elements in routine clinical diagnostics of haematological malignancies. Currently established methods such as metaphase cytogenetics, FISH or array-based approaches have limitations due to their dependency on viable cells, high costs or semi-quantitative nature. Importantly, they cannot be used on low abundance DNA. We therefore aimed to establish a robust and quantitative technique that overcomes these shortcomings. Methods For precise determination of del(5q) cell fractions, we developed an inexpensive multiplex- PCR assay requiring only nanograms of DNA that simultaneously measures allelic imbalances of 12 independent short tandem repeat markers. Results A pplication of this method to n=1142 samples from n=260 individuals revealed strong intermarker concordance (R2=0.77-0.97) and reproducibility (mean SD: 1.7%). Notably, the assay showed accurate quantification via standard curve assessment (R2>0.99) and high concordance with paired FISH measurements (R2=0.92) even with subnanogram amounts of DNA. Moreover, cytogenetic response was reliably confirmed in del(5q) patients with myelodysplastic syndromes treated with lenalidomide. While the assay demonstrated good diagnostic accuracy in receiver operating characteristic analysis (area under the curve: 0.97), we further observed robust correlation between bone marrow and peripheral blood samples (R2=0.79), suggesting its potential suitability for less-invasive clonal monitoring. Conclusions I n conclusion, we present an adaptable tool for quantification of chromosomal aberrations, particularly in problematic samples, which should be easily applicable to further tumour entities.
AB - Background C ytogenetic aberrations such as deletion of chromosome 5q (del(5q)) represent key elements in routine clinical diagnostics of haematological malignancies. Currently established methods such as metaphase cytogenetics, FISH or array-based approaches have limitations due to their dependency on viable cells, high costs or semi-quantitative nature. Importantly, they cannot be used on low abundance DNA. We therefore aimed to establish a robust and quantitative technique that overcomes these shortcomings. Methods For precise determination of del(5q) cell fractions, we developed an inexpensive multiplex- PCR assay requiring only nanograms of DNA that simultaneously measures allelic imbalances of 12 independent short tandem repeat markers. Results A pplication of this method to n=1142 samples from n=260 individuals revealed strong intermarker concordance (R2=0.77-0.97) and reproducibility (mean SD: 1.7%). Notably, the assay showed accurate quantification via standard curve assessment (R2>0.99) and high concordance with paired FISH measurements (R2=0.92) even with subnanogram amounts of DNA. Moreover, cytogenetic response was reliably confirmed in del(5q) patients with myelodysplastic syndromes treated with lenalidomide. While the assay demonstrated good diagnostic accuracy in receiver operating characteristic analysis (area under the curve: 0.97), we further observed robust correlation between bone marrow and peripheral blood samples (R2=0.79), suggesting its potential suitability for less-invasive clonal monitoring. Conclusions I n conclusion, we present an adaptable tool for quantification of chromosomal aberrations, particularly in problematic samples, which should be easily applicable to further tumour entities.
UR - http://www.scopus.com/inward/record.url?scp=85026291552&partnerID=8YFLogxK
U2 - 10.1136/jmedgenet-2017-104528
DO - 10.1136/jmedgenet-2017-104528
M3 - Article
C2 - 28600436
AN - SCOPUS:85026291552
SN - 0022-2593
VL - 54
SP - 640
EP - 650
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 9
ER -